Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

97.530
-0.330-0.34%

Close Jan 17 16:00 ET

98.200
+0.670+0.69%

Pre 05:08 ET

194.99BMarket Cap11.45P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Novartis CEO Sees Benefits, Threats From Trump Presidency -- Market Talk
WSJ29minutes ago
Big Pharma's Drug Innovation Could Get a Boost Under Trump Presidency, Novartis CEO Says -- Market Talk
WSJ03:21 ET
LVMH Is Once Again the Largest Company in Europe by Market Cap
Seeking AlphaJan 20 09:35 ET
Jefferies Remains a Hold on Novartis AG (NOVN)
TipRanksJan 20 02:36 ET · Ratings
Novartis Obtains Temporary Court Order Blocking Generic Version of Entresto
MT NewswiresJan 17 07:27 ET
Legal Uncertainties and Patent Risks Lead to Hold Rating for Novartis AG
TipRanksJan 17 05:55 ET · Ratings

Comments

Stock_Drift

Dec 19, 2024 05:18

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...